Allianz-Slovenska Poistovna AS (XBRA:1SLP401E) Research & Development: €0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XBRA:1SLP401E Allianz-Slovenska Poistovna AS XBRA:1SLP401E
39 GF Score
Price €330.00
GF Value €317.59
! 2 Warning Signs
View Full Analysis

What is Allianz-Slovenska Poistovna AS Research & Development?

Allianz-Slovenska Poistovna AS XBRA:1SLP401E 39 Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus rates XBRA:1SLP401E with a GF Score™ of 39/100 and a GF Value™ of €317.59. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Allianz-Slovenska Poistovna AS's Research & Development for the six months ended in Dec. 2025 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

Allianz-Slovenska Poistovna AS  (XBRA:1SLP401E) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Allianz-Slovenska Poistovna AS Research & Development Related Terms

Allianz-Slovenska Poistovna AS Research & Development Historical Data

* Premium members only.

The historical data trend for Allianz-Slovenska Poistovna AS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allianz-Slovenska Poistovna AS Research & Development Chart

Allianz-Slovenska Poistovna AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Allianz-Slovenska Poistovna AS Semi-Annual Data
Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XBRA:1SLP401E
39GF Score
Allianz-Slovenska Poistovna AS XBRA:1SLP401E
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allianz-Slovenska Poistovna AS Research & Development Calculation

This is the expense the company spent on research and development.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Allianz-Slovenska Poistovna AS (XBRA:1SLP401E) has a Research & Development of €0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Allianz-Slovenska Poistovna AS and its competitors.
Is Allianz-Slovenska Poistovna AS's Research & Development too high?
Allianz-Slovenska Poistovna AS's current Research & Development is €0.0 Mil. Overall, Allianz-Slovenska Poistovna AS has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Allianz-Slovenska Poistovna AS's Research & Development compare to BRK.A and AIG?
Allianz-Slovenska Poistovna AS's Research & Development of €0.0 Mil can be compared against companies in the Insurance industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Insurance company?
A good Research & Development depends on the Insurance industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Allianz-Slovenska Poistovna AS and its competitors. Allianz-Slovenska Poistovna AS's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allianz-Slovenska Poistovna AS stock overvalued right now?
Allianz-Slovenska Poistovna AS (XBRA:1SLP401E) has a current Research & Development of €0.0 Mil. The stock's GF Value™ is €317.59, compared to a current price of €330.00 — trading 3.9% above its estimated fair value. The current Research & Development is €0.0 Mil. Allianz-Slovenska Poistovna AS's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Allianz-Slovenska Poistovna AS (XBRA:1SLP401E), the current Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Allianz-Slovenska Poistovna AS (XBRA:1SLP401E) Overvalued in 2026?

Based on GuruFocus' analysis, Allianz-Slovenska Poistovna AS stock appears to be overvalued. The current stock price of €330.00 is trading 3.9% above its estimated GF Value™ of €317.59.

Key valuation signals for XBRA:1SLP401E:

  • Research & Development: €0.0 Mil
  • GF Value™: €317.59 vs. price of €330.00 (3.9% above fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the XBRA:1SLP401E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Allianz-Slovenska Poistovna AS Business Description

Address Dostoyevsky rad 4, Bratislava, SVK, 815 74
Allianz-Slovenska Poistovna AS is an insurance company. It offers insurance products ranging from life and accident insurance, insurance through private property and motor liability insurance to the insurance industry and entrepreneurs. The company serves small and medium size business and large companies.
39GF Score

Get the complete analysis for XBRA:1SLP401E

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€330.00
Price
€317.59
GF Value